SCHEMBL3655673

SCHEMBL3655673

Fc1ccc(Oc2ccc(Nc3cccc(N4CCOCC4)c3)nc2)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.54
CDK2 P24941 3/20 0.50
CCNT1 O60563 2/20 0.50
CDK9 P50750 2/20 0.50
CCNE1 P24864 1/20 0.50
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
TTBK1 Q5TCY1 1/20 0.45
TTBK2 Q6IQ55 1/20 0.45
TGFBR1 P36897 1/20 0.45
RIPK2 O43353 1/20 0.44
CCNA2 P20248 2/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CDK7 P50613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655694 0.90 MET (0.63) METCDK2CCNT1CDK9CCNE1
SCHEMBL3657530 0.88 CTSC (0.47) METCDK2CCNT1CDK9CCNE1
SCHEMBL8068266 0.85 MET (0.49) METCDK2CCNT1CDK9CCNE1
SCHEMBL3651256 0.84 MET (0.51) METCDK2CDK9TGFBR1RIPK2
SCHEMBL8064837 0.84 MET (0.51) METCDK2CCNT1CDK9CCNE1
SCHEMBL3648802 0.84 HTT (0.43) METKCNH2MAPK10JAK2JAK1
SCHEMBL3652459 0.82 EPHX2 (0.54) CDK2CCNE1
SCHEMBL3655868 0.81 DGAT1 (0.51) METGABRG2GABRB3GABRA5TGFBR1
SCHEMBL13058517 0.81 TNIK (0.54) KCNH2MAPK10
SCHEMBL3655248 0.79 TYK2 (0.46) METMAPK10JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
EP-2205317-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2010-07-14 EP disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HCRTR1, HCRTR2, RTN3 MET 463/4885CDK2 4492/4885CCNT1 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.